It suggests that EGFR + /TP53 + is prone to promote the growth, invasion and metastasis of tumor cells [45, 46], thus affecting the survival and prognosis of patients with tyrosine kinase inhibitor (TKI) treatment. This evidence concerns the gene TP53 and neoplasm.